HCWB heads into its May 22 earnings report in one of the most extreme short-side configurations of any small-cap biotech currently on the market.
The borrow market has essentially seized up. Availability has collapsed to 0% — every share in the lending pool is currently lent out — matching the 52-week low and leaving no room for new shorts to enter without paying up dramatically. Cost to borrow has surged to 772% annualised, more than double where it was a week ago at 448%, and more than double the already-elevated ~330% level that persisted through most of April. That's not a squeeze in progress — it's a borrow market that's already fully locked.
Short interest has been building in a near-vertical climb. The estimated short position reached 19.5% of the free float as of May 18, up from just 2.6% on May 8. That's a tenfold increase in ten trading days. The ORTEX short score now reads 80.6, up sharply from 63.6 on May 8, placing the stock among the most heavily shorted names in the ORTEX universe by percentile. The combination of extreme short concentration, zero availability, and a cost to borrow that has tripled in a week describes a lending market under severe stress — not a position that shorts can easily manage or add to.
The price tells a chaotic story. The stock closed at $1.06 on May 19, down 21% on the day, after a 212% surge over the prior week. That spike followed the May 14 earnings event, which triggered a 249% single-day move. The stock has now retraced sharply from whatever peak that announcement catalysed. Close peers and fell 18% and 9% respectively on the same day, suggesting some sector-level pressure, but HCWB's move dwarfs the peer group. The recent score note flags deep fundamental stress — a Z-score of -8.65, ROA of -27.2, and an F-score of just 1 — pointing to acute balance sheet deterioration as the structural backdrop to all the volatility.
Analyst coverage is thin and stale. The only on-record price target is $2.00, as of March 2026, but the sole recent analyst action — Maxim Group cutting its target from $120 to $35 in May 2025 — suggests the consensus view has been recalibrated sharply downward over the past year. That data should be treated as historical context rather than current guidance.
The May 22 print therefore faces an unusual test: whether any fundamental update can resolve the extreme tension between a stock that has moved +200% and -21% in the same week, a borrow market with no capacity left, and a short position that has built rapidly in anticipation of further deterioration.
See the live data behind this article on ORTEX.
Open HCWB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
